Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) have received a consensus rating of “Hold” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $6.83.

Several research analysts have recently commented on the company. ValuEngine downgraded Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research lowered Arbutus Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, December 4th. B. Riley raised Arbutus Biopharma from a “neutral” rating to a “buy” rating and cut their price target for the stock from $11.50 to $9.00 in a report on Tuesday, October 16th. Wedbush raised Arbutus Biopharma from an “underperform” rating to a “neutral” rating and set a $5.00 price target for the company in a report on Monday, October 15th. They noted that the move was a valuation call. Finally, Chardan Capital cut their price target on Arbutus Biopharma from $12.00 to $6.50 and set a “buy” rating for the company in a report on Friday, October 12th.

Several hedge funds have recently modified their holdings of ABUS. BlackRock Inc. raised its position in shares of Arbutus Biopharma by 246.6% in the second quarter. BlackRock Inc. now owns 2,391,143 shares of the biopharmaceutical company’s stock worth $17,455,000 after buying an additional 1,701,237 shares in the last quarter. EcoR1 Capital LLC purchased a new stake in shares of Arbutus Biopharma in the third quarter worth $11,641,000. EAM Investors LLC purchased a new stake in shares of Arbutus Biopharma in the third quarter worth $3,241,000. Northern Trust Corp purchased a new stake in shares of Arbutus Biopharma in the second quarter worth $2,164,000. Finally, Morgan Stanley raised its position in shares of Arbutus Biopharma by 39.4% in the third quarter. Morgan Stanley now owns 1,025,353 shares of the biopharmaceutical company’s stock worth $9,690,000 after buying an additional 289,556 shares in the last quarter. Institutional investors own 42.59% of the company’s stock.

Shares of ABUS traded down $0.01 during trading hours on Friday, reaching $3.74. The company had a trading volume of 7,046 shares, compared to its average volume of 228,054. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $211.92 million, a PE ratio of -2.08 and a beta of 1.62. Arbutus Biopharma has a 12-month low of $3.20 and a 12-month high of $12.60.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.13). The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $0.23 million. Arbutus Biopharma had a negative net margin of 1,116.69% and a negative return on equity of 91.36%. On average, research analysts anticipate that Arbutus Biopharma will post -1.49 EPS for the current year.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).

Further Reading: What are no-load funds?

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.